Short-course radiation plus AK112 for mismatch repair-proficient rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug (AK112) given after a short course of radiation. It is for people with a specific type of mid-low rectal cancer that has not spread and has not been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your tumor is a type called pMMR/MSS (meaning it is not the kind that usually responds to immunotherapy alone).
- The lower edge of your tumor is within about 7 inches of the anal opening.
- Your tumor is at a stage where it has not spread to far-away organs (stage cT2-4 and/or N+ but not T4b, N2, or involved lymph nodes outside the pelvis).
- You have not had prior cancer treatment for this rectal cancer.
- You are generally well enough to carry out daily activities (ECOG score 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining short-course radiation with an immune therapy drug (AK112) plus chemotherapy before surgery is better than radiation alone for locally advanced rectal cancer. It aims to shrink tumors and improve outcomes without needing stronger treatments later.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests a new combination of short-course radiation, a targeted drug (fruquintinib), and an immunotherapy drug (PD-1 inhibitor) to treat rectal cancer before surgery. It aims to shrink the tumor and improve outcomes for patients with a specific type of rectal cancer.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
This trial tests whether a short course of radiation followed by an immunotherapy drug (PD-L1 inhibitor) plus chemotherapy works as well as or better than a longer radiation course for locally advanced rectal cancer. The goal is to shrink tumors before surgery.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.